Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 11/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | ACACA | Q13085 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23680853 | 0.89 | HPGD (0.54) | HPGDALDH1A1LRRK2MEN1KMT2A | |
| SCHEMBL24929596 | 0.82 | HPGD (0.57) | HPGDALDH1A1LRRK2ACACBACACA | |
| SCHEMBL23675180 | 0.81 | HPGD (0.58) | HPGDALDH1A1LRRK2ACACBACACA | |
| SCHEMBL24328740 | 0.77 | HPGD (0.48) | HPGDLRRK2ACACBACACA | |
| SCHEMBL24463704 | 0.77 | HPGD (0.68) | HPGDALDH1A1KMT2APOLBADORA2A | |
| SCHEMBL23680614 | 0.77 | HPGD (0.69) | HPGDALDH1A1POLBADORA2A | |
| SCHEMBL23675318 | 0.76 | MAPK1 (0.53) | HPGDALDH1A1PIK3CDPIK3CAMTOR | |
| SCHEMBL28883069 | 0.75 | CRBN (0.54) | HPGDALDH1A1POLBTSHR | |
| SCHEMBL30361540 | 0.75 | HPGD (0.67) | HPGDALDH1A1 | |
| SCHEMBL29259945 | 0.75 | HPGD (0.67) | HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240374579-A1 | BICYCLIC PGDH INHIBITORS AND METHODS OF MAKING AND USING | EPIRIUM BIO INC. | 2024-11-14 | — | — | US | disclosed |
| EP-4377314-A1 | BICYCLIC PGDH INHIBITORS AND METHODS OF MAKING AND USING | Epirium Bio Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| WO-2023009618-A1 | BICYCLIC PGDH INHIBITORS AND METHODS OF MAKING AND USING | EPIRIUM BIO, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2023009618-A1 | BICYCLIC PGDH INHIBITORS AND METHODS OF MAKING AND USING | EPIRIUM BIO, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374579-A1 | BICYCLIC PGDH INHIBITORS AND METHODS OF MAKING AND USING | HPGD, HPGDS, GCDH | HPGD 1/4885ALDH1A1 224/4885LRRK2 4690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.